Report cover image

Type 1 Diabetes: 68-Market Analysis and Sales Forecast

Publisher GlobalData
Published Jan 15, 2025
Length 17 Pages
SKU # GBDT19541568

Description

Type 1 Diabetes: 68-Market Analysis and Sales Forecast

Summary

This report covers the 68 geographical markets and provides an Excel-based forecast model for the type 1 diabetes market from 2023-2033.

This publication is an expanded version of the Excel model containing the patient-based forecast (PBF) sales for type 1 diabetes, covered in GlobalData’s report “Type 1 Diabetes: Seven-Market Drug Forecast and Market Analysis”, published in January 2025. In addition to PBF sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 61 geographical markets (61M), totaling 68 markets (68M). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare and POLI Price Intelligence databases. For more information on the methodology and assumptions used in GlobalData’s forecast extrapolations, please refer to the Methodology and Assumptions tabs in the Excel model for this report.

Scope
  • Overview of type 1 diabetes, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized glaucoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the glaucoma therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for glaucoma treatment. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the global glaucoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 68MM type 1 diabetes therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 68MM type 1 diabetes therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

17 Pages
Table of Contents
1 Executive Summary
1.1 Overview
1.2 68M summary statistics
1.3 Key 7MM events driving the 68M forecast extrapolation
2 Appendix
2.1 Abbreviations
2.2 Methodology
2.2.1 Patient-based forecast methodology
2.2.2 68M forecast extrapolation methodology
2.3 Primary research - key opinion leaders and payers interviewed for this report
2.3.1 Key opinion leaders
2.4 Primary research - prescriber survey
2.5 About the authors
2.5.1 Analyst
2.5.2 Therapy area directors
2.5.3 Vice President of Disease Intelligence and Epidemiology
2.5.4 Global Head and EVP of Healthcare Operations and Strategy
About GlobalData
Contact Us
List of Tables
Table 1: Type 1 diabetes market size across the 68M - 7MM versus 61M
Table 2: Type 1 diabetes market size across the 68M - by geographical region
Table 3: Type 1 diabetes, key events occurring in the 7MM driving forecast trajectory in the 68M
Table 4: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: 7MM, total prevalent cases of HIV, both sexes, N, all ages, 2023 and 2033
Figure 2: 7MM, diagnosed prevalent cases of HIV, both sexes, N, all ages, 2023 and 2033
Figure 3: 7MM, diagnosed incident cases of HIV, both sexes, N, all ages, 2023 and 2033
Figure 4: 7MM, total prevalence of HIV, both sexes, %, all ages, 2013-33
Figure 5: 7MM, diagnosed prevalence of HIV, both sexes, %, all ages, 2013-33
Figure 6: 7MM, diagnosed incidence of HIV, both sexes, %, all ages, 2013-33
Figure 7: 7MM, sources used to forecast the total prevalent cases of HIV
Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of HIV
Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of HIV with HBV or HCV coinfection
Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of HIV on ART
Figure 11: 7MM, sources used to forecast the diagnosed incident cases of HIV in the 7MM
Figure 12: 7MM, sources used to forecast the population on PrEP in the 7MM
Figure 13: 7MM, sources used to forecast the PEP coverage in the 7MM
Figure 14: 7MM, total prevalent cases of HIV, N, both sexes, all ages, 2023
Figure 15: 7MM, diagnosed prevalent cases of HIV, N, both sexes, all ages, 2023
Figure 16: 7MM, diagnosed prevalent cases of HIV by age, N, both sexes, 2023
Figure 17: 7MM, diagnosed prevalent cases of HIV by sex, N, all ages, 2023
Figure 18: 7MM, diagnosed prevalent cases of HIV with HBV/HCV coinfection, N, both sexes, all ages, 2023
Figure 19: 7MM, diagnosed prevalent cases of HIV on ART, N, both sexes, all ages, 2023
Figure 20: 7MM, diagnosed incident cases of HIV, N, both sexes, all ages, 2023
Figure 21: 7MM, diagnosed incident cases by age, N, both sexes, 2023
Figure 22: 7MM, diagnosed incident cases of HIV by sex, all ages, 2023
Figure 23: 7MM, prophylactic population on PrEP, N, both sexes, all ages, 2023
Figure 24: 7MM, prophylactic population on PEP, N, both sexes, all ages, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us